NCT00089661 - AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer | Biotech Hunter

Enrollment

252

Participants

Timeline

Start Date

October 1, 2004

Primary Completion Date

May 11, 2007

Study Completion Date

May 27, 2009

Conditions

Breast CancerLow Bone Mineral DensityOsteopenia

Interventions

DRUG

Placebo

60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months

DRUG

AMG 162 / Denosumab

60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months